

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

COMMUNICATION

A preorganized β -amino acid bearing a guanidinium side chain and its use in cell-penetrating peptides

Cite this: DOI:
10.1039/x0xx00000x

Yosuke Demizu,^{*a,b} Makoto Oba,^c Koyo Okitsu,^{b,d} Hiroko Yamashita,^{b,d} Takashi Misawa,^b Masakazu Tanaka,^c Masaaki Kurihara,^{b,d} and Samuel H. Gellman^a

Received 00th January 2012,
Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

A cyclic β -amino acid (APC^{Gu}) bearing a side-chain guanidinium group has been developed. The APC^{Gu} residue was incorporated into an α/β -peptide based on the Tat(47-57) fragment, leading to an oligomer with substantial helicity in methanol that enters HeLa cells much more readily than does the corresponding Tat α -peptide.

Cell-penetrating peptides (CPPs) can deliver various molecules, including drugs, proteins, and DNA, into cells.¹⁻⁵ To date, a variety of CPPs has been developed, many of which are rich in arginine, including oligo-arginines (Arg)_n and the HIV Tat(47-57) peptide.⁶⁻¹¹ The guanidino moiety of Arg appears to play a crucial role in the cell entry process,⁶⁻⁹ and the internalization of those CPPs is occur via endocytosis as one of the major route of the endocytic uptake. However, in the presence of counterions such as pyrenebutyrate, the CPPs such as (Arg)₈ were internalized by direct translocation through plasma membranes.¹² Indeed, many unnatural oligomers that present multiple guanidino side chains, including peptoids,¹³ α -peptides,¹⁴ β -peptides,¹⁵⁻¹⁸ and oligocarbametes¹⁹ can enter cells. Previously it was shown that the efficiency of cell entry by β -peptides can be enhanced by increasing helicity.²⁰ This conformational stabilization was achieved by using cyclic β residues. Here we extend this concept to oligomers with a heterogeneous backbone, containing both α - and β -amino acid residues (" α/β -peptides").

α/β -Peptides containing 25-33% β residues that are evenly distributed among the α residues have been shown to adopt a helical conformation that is very similar to the well-known α -helix formed by pure α -peptide backbones.²¹⁻²⁴ This type of α/β -peptide helix can be stabilized by use of β residues with a five-membered ring constraint and *trans* disposition of the amino and carboxyl groups. Two specific examples of this type of constrained β residue have been widely explored, *trans*-2-aminocyclopentane-1-carboxylic acid (ACPC) and *trans*-4-aminopyrrolidine-3-carboxylic acid (APC). The pyrrolidine ring amino group of APC can be used to attach other peripheral units.²⁵ Here we introduce a new derivative of APC in which the pyrrolidine nitrogen forms part of a guanidino group (APC^{Gu}). We describe the preparation of a protected β -amino acid

that can be used to incorporate APC^{Gu} residues via solid-phase synthesis. In addition, we evaluate the cell-penetrating ability of an APC^{Gu}-containing α/β -peptide based on Tat (47-57),^{26,27} and we show that the helicity provided by the new β residue correlates with enhanced activity.





Fig. 1 Chemical structures of (S,S)-APC and (S,S)-APC^{Gu}.

The synthetic route to Fmoc-(S,S)-APC^{Gu}-OH (**3**) is shown in Scheme 1. Fmoc-(S,S)-APC^{Boc}-OH (**1**) was prepared by the reported method.²⁸ The side-chain Boc group was removed under acidic conditions to give Fmoc-(S,S)-APC-OH (**2**) in quantitative yield. Guanidinylation of the side-chain amino group in **2** was accomplished by treatment with 3 equivalents of N,N'-di-Boc-N''-triflylguanidine under basic conditions.²⁹



Scheme 1 Synthesis of Fmoc-(S,S)-APC^{Gu}-OH (**3**).

Building block **3** was used to prepare an α/β -peptide analogue of Tat(47-57) containing APC^{Gu} residues at positions 3, 7 and 10, to generate **Tat-1**. Two analogous α/β -peptides were prepared as well, **Tat-2**, which has β -Arg at positions 3, 7 and 10, and **Tat-3**, which has APC at these three positions. Two versions of the α -peptide Tat and the three α/β -peptides were synthesized, one set bearing N-terminal fluorescein (6FAM)

labels (**F-Tat**, **F-Tat-1**, **F-Tat-2** and **F-Tat-3**, and another set bearing acetyl groups at the N-termini (**Ac-Tat**, **Ac-Tat-1**, **Ac-Tat-2** and **Ac-Tat-3**). Microwave-assisted solid-phase methods were used in each case, and each peptide was purified by reverse-phase HPLC and characterized by MALDI mass spectrometry.³⁰




Fig. 2 Sequences of Tat derivatives **Tat**, **Tat-1-3**.

We examined the abilities of **F-Tat** and the three analogous α/β-peptides **F-Tat-1-3** to enter HeLa cells. After incubation of cells with each compound for 2 h at 37 °C, the cells were lysed, and the fluorescence intensity of the lysate was measured. The α/β-peptides entered cells more efficiently than the α-peptide **F-Tat**. In particular, **F-Tat-1**, containing (S,S)-APC^{Glu} (Z^β) residues, showed a 65-fold higher extent of entry relative to **F-Tat** (Figure 3).




Fig. 3 Cellular uptake of **F-Tat**, **F-Tat-1-3** at concentrations of 1 μM (incubation time: 2 hr). Error bars represent standard deviation, n = 5. *p<0.05, **p<0.01.

Figure 4 shows the effects of three endocytosis pathway inhibitors on entry of **F-Tat** and **F-Tat-1-3** into HeLa cells.³¹⁻³⁴ Amiloride is an inhibitor of macropinocytosis,^{33,34} chlorpromazine is an inhibitor of clathrin-mediated endocytosis,³² and filipin is an inhibitor of caveolae-mediated endocytosis.³²⁻³⁴ None of these agents hindered the uptake of α-peptide **F-Tat** or **F-Tat-2** (β residues = β³-hArg) which suggests that cell entry by these two molecules involves pathways other than the three we inhibited. In contrast, amiloride inhibited cell entry by **F-Tat-3** (β residues = APC), which suggests that macropinocytosis is at least partially responsible for entry in this case. The uptake level of **F-Tat-1** having (β residues = APC^{Glu}) was inhibited by both amiloride

and chlorpromazine, which suggests that both macropinocytosis and clathrin-mediated endocytosis contribute to cell entry in this case. Low temperature (4°C) incubation almost completely inhibited the internalization of **F-Tat** and **F-Tat-1-3** (Figure S2), suggesting that those peptides were mainly internalized into the cells via endocytosis.




Fig. 4 Effects of inhibitors on internalization of **F-Tat**, **F-Tat-1-3** at concentrations of 1 μM (incubation time: 2 hr). Error bars represent standard deviation, n = 5. *p<0.05, **p<0.01.

The intracellular distribution of **F-Tat** and α/β-peptides **F-Tat-1-3** (green) in HeLa cells was assessed by confocal laser scanning microscopy (CLSM) after staining late endosomes/lysosomes with LysoTracker Red (red) and nuclei with Hoechst 33342 (blue). All four peptides co-localized with the late endosomes/lysosomes, as shown in Figure 5.^{35,36} Roughly 50% of **F-Tat**, **F-Tat-2** and **F-Tat-3** were localized in the late endosomes/lysosomes, while <30% of **F-Tat-1** was localized in this way. This difference could arise if the distinctive entry mechanism of **F-Tat-1**, involving both macropinocytosis and clathrin-mediated endocytosis, causes this molecule to be delivered to a different sub-cellular region relative to the other three. An alternative possibility is that **F-Tat-1** is better able to move out of vesicles than the other three peptides, and therefore most of the **F-Tat-1** fluorescence is diffusely distributed throughout the cytoplasm.^{37,38} Research to clarify the underlying mechanism of **F-Tat-1** is now under way in our group, and the results will be reported elsewhere in the near time.




Fig. 5 Intracellular distribution of **F-Tat**, **F-Tat-1-3** (green) at concentrations of 1 μ M (incubation time: 2 hr). The acidic late endosomes/lysosomes were stained with LysoTracker Red (red) and the nuclei were stained with Hoechst 33342 (blue). (A) CLSM images of HeLa cells treated with Tat peptide derivatives. The scale bars represent 20 μ m. (B) Quantification of Tat peptide derivatives colocalized with LysoTracker Red. Error bars in the graph represent standard deviation, $n = 15$. ** $p < 0.01$.

The conformations of **Ac-Tat** and **Ac-Tat-1-3** were analyzed via circular dichroism (CD) in MeOH (Figure 6). The α/β -peptides containing cyclic β residues (**Ac-Tat-1** and **Ac-Tat-3**) showed a minimum at around 207 nm, which is similar to the minima observed in CD spectra of α/β -peptides that form right-handed (*P*) helices (Figure 6).^{39,40} Furthermore, addition of 10 mM SDS has little effect on the helical structures of **Tat-1** and **Tat-3** (Figure S3). On the other hand, **Ac-Tat** and **Ac-Tat-2**, which contain exclusively acyclic residues, show weaker CD signatures that suggest little or no folding.




Fig. 6 CD spectra in the 190–260 nm region of **Ac-Tat** (green), **Ac-Tat-1** (red), **Ac-Tat-2** (blue), and **Ac-Tat-3** (black). Peptide concentration: 30 μ M in MeOH solution.

Conclusions

Tat-1 with (*S,S*)-APC^{G_u} (**Z⁸**), **Tat-2** with β^3 -Arg (**R₆**), and **Tat-3** with (*S,S*)-APC (**Z**) showed higher cell penetrating activities than the α -peptide Tat in HeLa cells. In particular, **Tat-1** showed a 65-fold higher permeability than **Tat**. These results

indicate that stabilization of a helical secondary structure is synergistic with the presence of guanidino groups in promoting cell entry. It is noteworthy that **Tat-3** which contains (*S,S*)-APC residues and only three guanidino groups (on the three Arg residues) enters cells relatively efficiently. The new cyclic β -amino acid residue APC^{G_u}, which combines the advantages of conformational preorganization and a side-chain guanidino group should prove to be a useful tool for further development of biologically active β -peptides and α/β -peptides.

Acknowledgements

This study was supported, in part, by JSPS postdoctoral fellowships for research abroad (Y.D.), and by JSPS KAKENHI Grant Numbers 26460169 (Y.D.). Work at UW-Madison was supported in part by NSF grant CHE-1307365.

Notes and references

- ^a Department of Chemistry, University of Wisconsin 1101 University Avenue, Madison, WI 53707 (USA). E-mail: demizu@nihs.go.jp
- ^b National Institute of Health Sciences Setagaya, Tokyo 1588501 (Japan).
- ^c Graduate School of Biomedical Sciences, Nagasaki University Bunkyo-machi, Nagasaki 8528521 (Japan).
- ^d Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology Yokohama 2268501 (Japan)

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/c000000x/

- 1 I. Nakase, H. Akita, K. Kogure, A. Gráslund, Ü. Langel, H. Harashima, S. Futaki, *Acc. Chem. Res.*, 2012, **45**, 1132-1139.
- 2 J. M. Hyman, E. I. Geihe, B. M. Trantow, B. Parvin, P. A. Wender, *Proc. Natl. Acad. Sci. U.S.A.*, 2012, **109**, 13225-13230.
- 3 G. K. Seward, Q. Wei, I. J. Dmochowski, *Bioconjugate Chem.*, 2008, **19**, 2129-2135.
- 4 B. Gupta, T. S. Levchenko, V. P. Torchilin, *Adv. Drug Deliv. Rev.*, 2005, **57**, 637-651
- 5 T. Nagakubo, Y. Demizu, Y. Kanda, T. Misawa, T. Shoda, K. Okuhira, Y. Sekino, M. Naito, M. Kurihara, *Bioconjugate Chem.* 2014, **25**, 1921-1924.
- 6 C. M. Yamazaki, I. Nakase, H. Endo, S. Kishimoto, Y. Mashiyama, R. Masuda, S. Futaki, T. Koide, *Angew. Chem. Int. Ed.*, 2013, **52**, 5497-5500.
- 7 S. B. Fonseca, M. P. Pereira, S. O. Kelley, *Adv. Drug Deliv. Rev.* 2009, **61**, 953-964.
- 8 P. A. Wender, C. Wesley, E. A. Galliher, L. R. Jones, T. H. Pillow, *Adv. Drug Deliv. Rev.*, 2008, **60**, 452-472.
- 9 S. Futaki, *Biopolymers*, 2006, **84**, 241-249.
- 10 E. Dupont, A. Prochiantz, A. Joliot, *Penetratin Story: an Overview. Methods Mol. Biol.*, 2011, **683**, 21-29.
- 11 X. Wang, I. Huq, T. M. Rana, *J. Am. Chem. Soc.*, 1997, **119**, 6444-6445.
- 12 T. Takeuchi, M. Kosuge, A. Tadokoro, Y. Sugiura, M. Nishi, M. Kawata, N. Sakai, S. Matille, S. Futaki, *ACS Chem. Biol.*, 2006, **1**, 299-303.

- 13 P. A. Wender, D. J. Mitchell, K. Pattabiraman, E. T. Pelkey, L. Steinman, J. B. Rothbard, *Proc. Natl. Acad. Sci. U.S.A.*, 2000, **97**, 13003-13008.
- 14 J. Kuriakose, V. Hernandez, M. Nepal, A. Brezden, V. Pozzi, M. Seleem, J. Chmielewski, *Angew. Chem. Int. Ed.*, 2013, **52**, 9664-9667.
- 15 C. M. Goodman, S. Choi, S. Shandler, W. F. DeGrado, *Nat. Chem. Biol.*, 2007, **3**, 252-262.
- 16 D. Seebach, A. K. Beck, D. J. Bierbaum, *Chem. Biodivers.*, 2004, **1**, 1111-1239.
- 17 R. P. Cheng, S. H. Gellman, W. F. DeGrado, *Chem. Rev.*, 2001, **101**, 3219-3232.
- 18 S. H. Gellman, *Acc. Chem. Res.*, 1998, **31**, 173-180.
- 19 P. A. Wender, J. B. Rothbard, T. C. Jessop, E. L. Kreider, B. L. Wylie, *J. Am. Chem. Soc.*, 2002, **124**, 13382-13383.
- 20 T. B. Potocky, A. K. Menon, S. H. Gellman, *J. Am. Chem. Soc.*, 2005, **127**, 3686-3687.
- 21 L. M. Johnson, S. H. Gellman, *Methods Enzymol.*, 2013, **523**, 407-429.
- 22 H. S. Haase, K. J. Peterson-Kaufman, S. K. Lan Levengood, J. W. Checco, W. L. Murphy, S. H. Gellman, *J. Am. Chem. Soc.*, 2012, **134**, 7652-7655.
- 23 M. D. Boersma, H. S. Haase, K. J. Peterson-Kaufman, E. F. Lee, O. B. Clarke, P. M. Colman, B. J. Smith, W. S. Horne, W. D. Fairlie, S. H. Gellman, *J. Am. Chem. Soc.*, 2012, **134**, 315-323.
- 24 J. L. Price, W. S. Horne, S. H. Gellman, *J. Am. Chem. Soc.*, 2010, **132**, 12378-12387.
- 25 H. -S. Lee, F. A. Syud, X. Wang and S. H. Gellman, *J. Am. Chem. Soc.*, 2001, **123**, 7721-7722.
- 26 T. B. Potocky, A. K. Menon, S. H. Gellman, *J. Biol. Chem.*, 2003, **278**, 50188-50194.
- 27 N. Umezawa, M. A. Gelman, M. C. Haigis, R. T. Raines, S. H. Gellman, *J. Am. Chem. Soc.*, 2002, **124**, 368-369.
- 28 H. S. Lee, P. R. LePlae, E. A. Porter, S. H. Gellman, *J. Org. Chem.*, 2001, **66**, 3597-3599.
- 29 K. Feichtinger, C. Zaph, H. L. Sings, M. Goodman, *J. Org. Chem.*, 1998, **63**, 3804-3805.
- 30 See the Supporting Information.
- 31 J. Rejman, A. Bragonzi, *Mol. Ther.*, 2005, **12**, 468-474.
- 32 S. K. Lai, K. Hida, S. T. Man, C. Chen, C. Machamer, T. A. Schroer, J. Hanes, *Biomaterials*, 2007, **28**, 2876-2884.
- 33 D. Mudhakir, H. Akita, E. Tan, H. Harashima, *J. Control. Release*, 2008, **125**, 164-173.
- 34 M. Oba, M. Tanaka, *Biol. Pharm. Bull.*, 2012, **35**, 1064-1068.
- 35 M. Oba, K. Aoyagi, K. Miyata, Y. Matsumoto, K. Itaka, N. Nishiyama, Y. Yamasaki, H. Koyama, K. Kataoka, *Mol. Pharmaceutics*, 2008, **5**, 1080-1092.
- 36 S. Takae, K. Miyata, M. Oba, T. Ishii, N. Nishiyama, K. Itaka, Y. Yamasaki, H. Koyama, K. Kataoka, *J. Am. Chem. Soc.*, 2008, **130**, 6001-6009.
- 37 I. Nakase, T. Takeuchi, G. Tanaka, S. Futaki, *Adv. Drug Deliv. Rev.*, 2008, **60**, 598-607.
- 38 M. M. Fretz, N. A. Penning, S. Al-Taei, S. Futaki, T. Takeuchi, I. Nakase, G. Storm, A. T. Jones, *Biochem. J.*, 2007, **403**, 335-342.
- 39 J. L. Price, W. S. Horne, S. H. Gellman, *J. Am. Chem. Soc.*, 2007, **129**, 6376-6377.
- 40 M. A. Schmitt, B. Weisblum, S. H. Gellman, *J. Am. Chem. Soc.*, 2007, **129**, 417-428.